Literature DB >> 2545775

Mutation of 3' splice sites in two different class I genes results in different usage of cryptic splice sites.

M L Hedley1, J Forman, P W Tucker.   

Abstract

To determine the pattern of alternative splicing at the 5' end of class I genes, the 3' splice sites bordering exon 2 of the H-2Dd and H-2Kd genes were mutated from AG to GG (H-2Dd) or CG (H-2Kd). The mutant genes were transfected into L cells, and RNA from clones expressing these Ag was used for analysis by RNase and S1 nuclease mapping techniques. The first intervening sequence of both class I genes contains several potential 3' splice acceptor sites. However, a clear preference for only one site was detected in each of the H-2Dd and H-2Kd mRNA. Examination of the endogenous H-Dd and H-2Kd class I transcripts in normal murine tissues and in tumors demonstrated that the alternatively spliced mRNAs were produced, but at a low frequency. Infection of transfected L cells or tumor lines with vesicular stomatitis virus altered the level of differentially spliced message in these cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545775

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Coexpression of mu and gamma 1 heavy chains can occur by a discontinuous transcription mechanism from the same unrearranged chromosome.

Authors:  M Nolan-Willard; M T Berton; P Tucker
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

2.  Identification of mutations in the alpha-L-iduronidase gene (IDUA) that cause Hurler and Scheie syndromes.

Authors:  H S Scott; T Litjens; P V Nelson; P R Thompson; D A Brooks; J J Hopwood; C P Morris
Journal:  Am J Hum Genet       Date:  1993-11       Impact factor: 11.025

3.  Splicing in Caenorhabditis elegans does not require an AG at the 3' splice acceptor site.

Authors:  R V Aroian; A D Levy; M Koga; Y Ohshima; J M Kramer; P W Sternberg
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.